Clinical Utility of Sero-Immunological Responses Against SARS-CoV-2 Nucleocapsid Protein During Subsequent Prevalence of Wild-Type, Delta Variant, and Omicron Variant-Reference-Cited by-同舟云学术

Clinical Utility of Sero-Immunological Responses Against SARS-CoV-2 Nucleocapsid Protein During Subsequent Prevalence of Wild-Type, Delta Variant, and Omicron Variant

Published:2023 Issue:37 Volume:38 Page:
ISSN:1011-8934
Container-title:Journal of Korean Medical Science
language:en
Short-container-title:J Korean Med Sci

Author:

Lee Beomki¹^ORCID,Ko Jae-Hoon²^ORCID,Baek Jin Yang³^ORCID,Kim Haein²^ORCID,Huh Kyungmin²^ORCID,Cho Sun Young²^ORCID,Kang Cheol-In²^ORCID,Chung Doo Ryeon²^ORCID,Peck Kyong Ran²^ORCID,Kang Eun-Suk¹^ORCID

Affiliation:

1. Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

2. Division of Infectious Diseases, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

3. Asia Pacific Foundation for Infectious Diseases (APFID), Seoul, Korea.

Funder

Korea Disease Control and Prevention Agency

Samsung Medical Center

Publisher

XMLink

Subject

General Medicine

Link